Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
4(57.1%)
Phase 2
3(42.9%)
7Total
Phase 1(4)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT07521007Phase 2Not Yet Recruiting

A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis

Role: lead

NCT06700720Phase 2Recruiting

YN001-004 in Patients With Coronary Atherosclerosis in Australia

Role: lead

NCT07309042Phase 1Not Yet Recruiting

Phase 1 Study of the Safety and Pharmacokinetics of YN001 With Rosuvastatin in Healthy Chinese Subjects

Role: lead

NCT07311330Phase 2Not Yet Recruiting

Phase IIa Clinical Trial of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile Dysfunction

Role: lead

NCT07190885Phase 1Recruiting

A Pharmacokinetic Study of YN001 in Healthy Participants

Role: lead

NCT06048588Phase 1Completed

YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis

Role: lead

NCT05635084Phase 1Completed

A First-in-human Study of YN001 in Healthy Volunteers

Role: lead

All 7 trials loaded